SkinBioTherapeutics Appoints Permanent CEO and Chair
SkinBioTherapeutics PLC appointed Rachel Parsonage as CEO and Alyson Levett as Chair on a permanent basis. The company also expects FY26 revenue growth of 20.5% to £4.70 million and an adjusted EBITDA loss of £1.60 million, before exceptional costs of £1.20 million. Trading in the early months of FY27 has been ahead of